Editas Medicine to Host Conference Call Discussing First Quarter 2019 Results and Corporate Update
April 30 2019 - 4:01PM
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing
company, today announced that it will host a conference call and
webcast on Tuesday, May 7, 2019, at 5:00 p.m. ET to discuss a
corporate update and results for the first quarter of 2019.
To access the call, please dial 844-348-3801 (domestic) or
213-358-0955 (international) and provide the passcode 8457858. A
live webcast of the presentation will be available on the Investors
& Media section of the Editas Medicine website.
About Editas Medicine As a leading genome
editing company, Editas Medicine is focused on
translating the power and potential of the CRISPR/Cas9 and
CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a
robust pipeline of treatments for people living with serious
diseases around the world. Editas Medicine aims to
discover, develop, manufacture, and commercialize transformative,
durable, precision genomic medicines for a broad class of diseases.
For the latest information and scientific presentations, please
visit www.editasmedicine.com.
Contacts:
Investors
Mark Mullikin
(617) 401-9083
mark.mullikin@editasmed.com
Media
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Sep 2023 to Sep 2024